PepGen Q2 net loss narrows as expenses fall

PepGen

06/08/2026 12:52

Overview
Biotechnology company's Q2 net loss narrowed yr/yr as operating expenses declined
Company ended Q2 with $117.2 mln in cash, sufficient to fund operations into Q4 2027
PepGen fully enrolled 10 mg/kg FREEDOM2-DM1 cohort; next data readout expected in November

Outlook
PepGen expects data from 10 mg/kg FREEDOM2-DM1 cohort in November
Company expects results from 12.5 mg/kg FREEDOM2-DM1 cohort in 1H 2027
PepGen says cash is sufficient to fund operations into Q4 2027

Result Drivers
R&D SPEND DOWN - Lower research and development expenses contributed to reduced net loss in Q2
CLINICAL PROGRESS - Advancement of FREEDOM2-DM1 study, including full enrollment of 10 mg/kg cohort and DSMB dose escalation recommendation, cited as key focus
ADMIN COSTS UP - General and administrative expenses increased yr/yr

Company press release: ID:nBw5rBSh2a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.26
 
Q2 Net Loss
 
$17.81 mln
 
Q2 Operating Expenses
 
$18.94 mln
 
Q2 Operating Income
 
-$18.94 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for PepGen Inc. is $10.50, about 430.3% above its August 5 closing price of $1.98

Reuters Recommended Reads
Aug 5 - Entrada Therapeutics Q2 net loss narrows on lower costs
Aug 5 - Biomea Fusion Q2 loss narrows, cash runway into Q2 2027
Aug 3 - Design Therapeutics Q2 net loss narrower than expected

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)